Media

The Economic Impact of Cystectomy vs Trimodal Bladder Therapy - Stephen Williams

Details
Zachary Klaassen and Stephen Williams delve into the economic and treatment implications of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Dr. Williams, with a collaborative team spanning medical oncology to economic experts, has spent over a decade exploring these treatment pathways, revealing significant cost differences and outcomes through extensive research, in...

Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans

Details
Alicia Morgans presents a meta-analysis, undertaken with colleagues, analyzing 14 phase three trials on treatment intensification in metastatic hormone-sensitive prostate cancer. The study scrutinizes outcomes between older and younger patients, revealing that older patients exhibit a slightly diminished benefit from intensified treatments compared to their younger counterparts. Despite this, the...

Adopting a Multidisciplinary Approach to Optimize Treatment Decisions for Patients with Metastatic Prostate Cancer - Michael Williams & Mark Fleming

Details
Michael Williams and Mark Fleming discuss their collaborative approach in managing patients with metastatic prostate cancer. Drs. Williams and Fleming emphasize the importance of multidisciplinary care, sharing a case of a patient with high-volume disease treated with an oral LHRH antagonist and enzalutamide. They highlight the need for open communication and decision-making between specialties to...

Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings - Andrea Apolo

Details
Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with pembrolizumab versus observation. However, overall survival data is still maturing. Patients who received pembrolizumab had a median disease-free survival of 29 months versus 14 months for the observation...

Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer - Amanda Nizam

Details
Amanda Nizam presents findings from the UNITE study at GU ASCO 2024, exploring enfortumab vedotin's (EV) efficacy in patients with advanced urothelial carcinoma post-platinum-based chemotherapy and maintenance avelumab. This retrospective analysis, involving 633 patients across 16 US sites, reveals that EV's outcomes are consistent with previous trials, even after maintenance avelumab. Despite exp...

The Role of Nephrectomy with Immunotherapy in Metastatic Renal Cell Carcinoma - Dimitrios Makrakis

Details
Dimitrios Makrakis presents a significant meta-analysis exploring the role of cytoreductive nephrectomy in patients undergoing immune checkpoint inhibition for metastatic renal cell carcinoma. This study, a substantial effort involving 2,319 patients, sought to address the gap in understanding post-CARMENA, focusing on outcomes in the era of immune checkpoint inhibitors. The analysis, utilizing in...

Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer - María Bourlon

Details
Pedro Barata and María Bourlon discuss the CheckMate 9ER trial's 55-month follow-up, revealing the enduring benefits of cabozantinib plus nivolumab over sunitinib in untreated advanced renal cell carcinoma. The trial highlights significant advancements in overall survival, progression-free survival, and response rates, alongside improved quality of life for patients. Dr. Bourlon emphasizes the tri...

Update on Biomarkers in Renal Cell Carcinoma - David Braun

Details
Pedro Barata and David Braun delve into the evolving landscape of biomarkers in renal cell carcinoma (RCC). Dr. Braun emphasizes the transition from histological analysis to advanced techniques like genomics and transcriptomics, highlighting their potential to differentiate between molecular subtypes of RCC and predict therapy responses. Specifically, transcriptomics could pave the way for tailore...

LIBERTAS Trial Tests Less Treatment, Better Quality of Life in Responding mHSPC Patients - Arun Azad

Details
Arun Azad discusses the LIBERTAS trial focusing on metastatic hormone-sensitive prostate cancer treatment with ADT plus apalutamide. The trial, aimed at improving patient outcomes and quality of life, explores the efficacy of deescalating therapy for patients achieving a PSA of less than 0.2 nanograms per milliliter after six months. The study includes a diverse patient population, irrespective of...

Integrating Telehealth into Urology, AUA's 2023 Quality Improvement Summit - Jennifer Robles & Kara Watts

Details
Kara Watts from Montefiore Medical Center and Jen Robles from Vanderbilt University Medical Center shared insights from the AUA's 2023 Quality Improvement Summit, which focused on integrating telehealth into urology. They discussed the importance of telehealth in providing safe, effective, and satisfactory care, especially for patients with sensitive needs or disabilities. Despite the decrease in...